{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:47:46Z","timestamp":1794635266435,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.ijpharm.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T07:58:00Z","timestamp":1433663880000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Enzymatic action of phospholipase A2 on liposomal drug delivery systems"],"prefix":"10.1016","volume":"491","author":[{"given":"Anders H.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole G.","family":"Mouritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Arouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2015.06.005_bib0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z","article-title":"Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer","volume":"74","author":"Abe","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.plipres.2004.12.001","article-title":"Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release","volume":"44","author":"Andresen","year":"2005","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cocis.2013.06.001","article-title":"Lipases, liposomes and lipid-prodrugs","volume":"18","author":"Arouri","year":"2013","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/08982104.2011.563365","article-title":"Anticancer double lipid prodrugs: liposomal preparation and characterization","volume":"21","author":"Arouri","year":"2011","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ejps.2011.09.013","article-title":"Phospholipase A2-susceptible liposomes of anticancer double lipid-prodrugs","volume":"45","author":"Arouri","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.plipres.2012.09.002","article-title":"Membrane-perturbing effect of fatty acids and lysolipids","volume":"52","author":"Arouri","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0035","doi-asserted-by":"crossref","first-page":"e0125508","DOI":"10.1371\/journal.pone.0125508","article-title":"Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release","volume":"10","author":"Arouri","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jbiotec.2009.08.015","article-title":"Luciferase protection against proteolytic degradation: a key for improving signal in nano-system biology","volume":"144","author":"Ataei","year":"2009","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(\u00ae)\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0050","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mc.20271","article-title":"Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth","volume":"46","author":"Belinsky","year":"2007","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0060","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1021\/cr990139w","article-title":"Interfacial enzymology: the secreted phospholipase A2 paradigm","volume":"101","author":"Berg","year":"2001","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/BF00186580","article-title":"Collection and concentration of tear proteins studied by SDS gel electrophoresis. Presentation of a new method with special reference to dry eye patients","volume":"232","author":"Bjerrum","year":"1994","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1388-1981(99)00188-2","article-title":"Anionic phospholipids, interfacial binding and the regulation of cell functions","volume":"1483","author":"Buckland","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl","key":"10.1016\/j.ijpharm.2015.06.005_bib0075","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1194\/jlr.R800033-JLR200","article-title":"Phospholipase A2 structure\/function, mechanism, and signaling","volume":"50","author":"Burke","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0080","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1096\/fj.12-207597","article-title":"Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer","volume":"26","author":"Cai","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0085","first-page":"49","article-title":"Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy","volume":"7","author":"Chang","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1529\/biophysj.108.128710","article-title":"Amyloid-type fiber formation in control of enzyme action: interfacial activation of phospholipase A2","volume":"95","author":"Code","year":"2008","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0005-2736(02)00659-4","article-title":"Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue","volume":"1609","author":"Davidsen","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0005-2736(02)00461-3","article-title":"Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes","volume":"1564","author":"Davidsen","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0105","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.ejca.2010.07.015","article-title":"Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation","volume":"46","author":"de Jonge","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s002490050003","article-title":"Miscibility of phosphatidylethanolamine\u2013phosphatidylglycerol mixtures as a function of pH and acyl chain length","volume":"28","author":"Garidel","year":"2000","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0115","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s002490050099","article-title":"The mixing behavior of pseudobinary phosphatidylcholine\u2013phosphatidylglycerol mixtures as a function of pH and chain length","volume":"26","author":"Garidel","year":"1997","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0120","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1096\/fasebj.8.12.8088457","article-title":"Inhibition of phospholipase A2","volume":"8","author":"Gelb","year":"1994","journal-title":"FASEB J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0125","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(74)90682-5","article-title":"Drug-carrier potential of liposomes in cancer chemotherapy","volume":"202","author":"Gregoriadis","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00249-005-0466-z","article-title":"Role of lipid protrusions in the function of interfacial enzymes","volume":"34","author":"Halperin","year":"2005","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0135","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1021\/bi960866a","article-title":"Systematic relationship between phospholipase A2 activity and dynamic lipid bilayer microheterogeneity","volume":"35","author":"H\u00f8nger","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0005-2736(01)00407-2","article-title":"Phospholipase A(2) activity towards vesicles of DPPC and DMPC\u2013DSPC containing small amounts of SMPC","volume":"1515","author":"H\u00f8yrup","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0145","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1039\/B314146B","article-title":"Lipid protrusions membrane softness, and enzymatic activity","volume":"6","author":"H\u00f8yrup","year":"2004","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11805-011-0562-z","article-title":"Cytosolic phospholipase A2 and its role in cancer","volume":"8","author":"Hu","year":"2011","journal-title":"Clin. Oncol. Cancer Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOL.0b013e328351b439","article-title":"Phospholipase A(2) enzymes in metabolic and cardiovascular diseases","volume":"23","author":"Hui","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.biochi.2011.07.029","article-title":"Lipids, curvature stress, and the action of lipid prodrugs: free fatty acids and lysolipid enhancement of drug transport across liposomal membranes","volume":"94","author":"Jespersen","year":"2012","journal-title":"Biochim."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0165","first-page":"1158","article-title":"Diversity of phospholipase A2 enzymes","volume":"27","author":"Kudo","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.biochem.76.062405.154007","article-title":"Biochemistry and physiology of mammalian secreted phospholipases A2","volume":"77","author":"Lambeau","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1875933501103010038","article-title":"Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer","volume":"3","author":"Landon","year":"2011","journal-title":"Open Nanomed. J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0180","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1529\/biophysj.105.070987","article-title":"Domain-induced activation of human phospholipase A2 type IIA: local versus global lipid composition","volume":"90","author":"Leidy","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0041-0101(79)90291-5","article-title":"Isolation and characterization of a toxic phospholipase A2 in the spitting cobra (Naja mossambica mossambica) venom","volume":"17","author":"Martin-Moutot","year":"1979","journal-title":"Toxicon"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000468890","article-title":"Development of a radioimmunoassay for human group-II phospholipase A2 and demonstration of postoperative elevation","volume":"45","author":"Matsuda","year":"1991","journal-title":"Enzyme"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0195","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0200","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0020-1790(80)90051-7","article-title":"Cobra venom phospholipase highly toxic to arthropods\u2014I. Purification and characterization","volume":"10","author":"Menashe","year":"1980","journal-title":"Insect Biochem."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0205","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.nano.2014.04.011","article-title":"Just so stories: the random acts of anti-cancer nanomedicine performance","volume":"10","author":"Moghimi","year":"2014","journal-title":"Nanomedicne"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0210","doi-asserted-by":"crossref","first-page":"S1293","DOI":"10.1088\/0953-8984\/18\/28\/S12","article-title":"Activation of interfacial enzymes at membrane surfaces","volume":"18","author":"Mouritsen","year":"2006","journal-title":"J. Phys. Condens. Matter"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0215","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00041433-200310000-00003","article-title":"New phospholipase A(2) isozymes with a potential role in atherosclerosis","volume":"14","author":"Murakami","year":"2003","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.alit.2014.07.005","article-title":"Secreted phospholipase A2 and mast cells","volume":"64","author":"Murakami","year":"2015","journal-title":"Allergol. Int."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0225","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.plipres.2010.12.001","article-title":"Recent progress in phospholipase A(2) research: from cells to animals to humans","volume":"50","author":"Murakami","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bjc.1993.294","article-title":"Expression of group-II phospholipase A2 in malignant and non-malignant human gastric mucosa","volume":"68","author":"Murata","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0041-0101(76)90118-5","article-title":"Temperature stability of phospholipase A activity. II. Variations in optimum temperature of phospholipases A2 from various snake venoms","volume":"14","author":"Nair","year":"1976","journal-title":"Toxicon"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0240","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/bio.648","article-title":"Enhanced firefly bioluminescent assay of adenosine 5\u2032-triphosphate using liposomes containing cationic cholesterols","volume":"16","author":"Nakata","year":"2001","journal-title":"Luminescence"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0245","first-page":"417","article-title":"Secretion of group II phospholipase A2 by lacrimal glands","volume":"35","author":"Nevalainen","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2014.02.018","article-title":"Targeted vs. non-targeted delivery systems: reduced toxicity over efficacy","volume":"178","author":"Park","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0255","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1021\/jm900091h","article-title":"Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs","volume":"52","author":"Pedersen","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0260","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1021\/jm100190c","article-title":"Liposomal formulation of retinoids designed for enzyme triggered release","volume":"53","author":"Pedersen","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0003-2697(02)00236-1","article-title":"Application of matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry for monitoring the digestion of phosphatidylcholine by pancreatic phospholipase A(2)","volume":"308","author":"Petkovic","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0270","doi-asserted-by":"crossref","first-page":"11044","DOI":"10.1021\/bi020244r","article-title":"Mechanism and kinetics of delta-lysin interaction with phospholipid vesicles","volume":"41","author":"Pokorny","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0275","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/prot.340090402","article-title":"Phospholipase A2 at the bilayer interface","volume":"9","author":"Ramirez","year":"1991","journal-title":"Proteins"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0280","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1021\/la2039834","article-title":"Characterization of fluorinated catansomes: a promising vector in drug-delivery","volume":"28","author":"Rosholm","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0285","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.biochi.2010.03.019","article-title":"Emerging roles for phospholipase A2 enzymes in cancer","volume":"92","author":"Scott","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0290","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1529\/biophysj.107.114363","article-title":"Activation of phospholipase A2 by ternary model membranes","volume":"94","author":"Simonsen","year":"2008","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0295","doi-asserted-by":"crossref","first-page":"48535","DOI":"10.1074\/jbc.M205855200","article-title":"Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2","volume":"277","author":"Singer","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(00)00105-0","article-title":"The expanding superfamily of phospholipase A2 enzymes: classification and characterization","volume":"1488","author":"Six","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0305","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/jnci\/djq324","article-title":"Cytosolic phospholipase A2(alpha) and cancer: a role in tumor angiogenesis","volume":"102","author":"Tosato","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0310","first-page":"3179","article-title":"Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue","volume":"27","author":"Tribler","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0315","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1567-5688(02)00045-4","article-title":"Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase","volume":"3","author":"Tselepis","year":"2002","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0005-2736(98)00084-4","article-title":"Increase in phospholipase A2 activity towards lipopolymer-containing liposomes","volume":"1373","author":"Vermehren","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2015.06.005_bib0325","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjc.1994.229","article-title":"Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency","volume":"69","author":"Yamashita","year":"1994","journal-title":"Br. J. Cancer"}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315005165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315005165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T02:17:56Z","timestamp":1656641876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517315005165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":65,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0378517315005165"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.06.005","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzymatic action of phospholipase A2 on liposomal drug delivery systems","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}